Nucleoside and nucleotide analogue reverse transcriptase inhibitors: A clinical review of antiretroviral resistance

Antiviral Therapy

Volumn 8, Issue 6, 2003, Pages 489-506

  Gallant, Joel E ^a   Gerondelis, Peter Z ^b   Wainberg, Mark A ^c   Shulman, Nancy S ^d   Haubrich, Richard H ^e   St Clair, Marty ^b   Lanier, Ernest R ^b   Hellmann, Nicholas S ^f   Richman, Douglas D ^e,g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROCHE MOLECULAR SYSTEMS   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; ENZYME INHIBITION; GENE INSERTION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NUCLEOSIDES; NUCLEOTIDES; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 0348223944     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
2. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 2003; 37:113-128.
3. Arion D & Parniak MA. HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resistance Update 1999; 2:91-95.
4. Gao H-Q, Boyer PL, Sarafianos SG, Arnold E & Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. Journal of Molecular Biology 2000; 300:403-418.
5. Larder BA & Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-1158.
6. Garcia-Lerma G, MacInnes H, Nidtha S, Bennet D, Weinstock H & Heneine W. In vitro selection of the T251Y and K65R mutations by stavudine and demonstration of high-level resistance to stavudine. Antiviral Therapy 2002; 7:S28. Abstract 31.
7. Ross L, Danehower S, Johnson M et al. Stavudine-based combination and monotherapy selects for zidovudine resistance HIV-1 mutations in zidovudine-naive adults and in paediatric patients. Antiviral Therapy 1999; 4(Suppl. 1):79. Abstract 115.
8. Ross L, Henry K, Paar D, Salvato P, Shaefer M, Fisher R, Liao Q & St Clair M. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens. Journal of Human Virology 2001; 4:217-222.
9. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW & Richman DD; International AIDS Society-USA. Drug resistance mutations in HIV-1. Topics in HIV Medicine 2002; 10:11-25.
10. Meyer PR, Pfeifer I, Matsuura S, Bazmi H, So AG, Mellors JW & Scott WA. Effects of M41L and T215Y mutations in HIV-1 reverse transcriptase on removal of chain-terminators from blocked primer/templates. Antiviral Therapy 2000; 5(Suppl. 3):14. Abstract 15.
11. Lanier ER, Hellmann N, Scott J, Ait-Khaled M, Melby T, Paxinos E, Werhane H, Petropoulos C, Kusaba E, St Clair M, Smiley L & Lafon S. Determination of a clinically relevant phenotypic resistance 'cutoff' for abacavir using the PhenoSense assay. Presented at: 8th Conference on Retroviruses & Opportunistic Infections; February 4-8 2001; Chicago, Ill., USA. Abstract 254.
12. Costagliola D, Descamps D, Calvez V, Masquelier B, Ruffault A, Telles F, Meynard JL & Brun-Vezinet F. Presence of thymidine associated mutations and response to d4T, abacavir and ddI in the control Arm of the Narval ANRS 088 Trial. Presented at: 8th Conference on Retroviruses & Opportunistic Infections; February 4-8, 2001; Chicago, Ill., USA. Abstract 450.
13. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10:975-981.
14. Emtriva [package insert]. Foster City, Calif., USA: Gilead Sciences, Inc.; 2003.
15. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, Tisdale M & Larder B. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. Journal of Infectious Diseases 2000; 181:912-920.
16. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T & Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrobial Agents & Chemotherapy 1997; 41:757-762.
17. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD & Larder BA. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.
18. Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S & Katlama C. M184V significantly delays the emergence of the T215F/T, D67N, and L210W mutations independently of VRNA and time on therapy. Presented at: 7th European Conference on Clinical Aspects & Treatment of HIV Infection; October 23-27 1999; Lisbon, Portugal. Abstract 1236.
19. Whitcomb JM, Paxinos E, Huang W, Maranta M, Limoli K, Chappey C, Parkin NT, Hellmann NS & Petropoulos CJ. The presence of nucleoside analog mutations (NAMs) is highly correlated with reduced susceptibility to all NRTIs. Presented at: 9th Conference on Retroviruses & Opportunistic Infections; February 24-28 2002, Seattle, Wash., USA. Abstract 569-T.
20. Winters MA, Bosch RJ, Albrecht MA & Katzenstein DA, for the ACTG 364 Study Team. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside-experienced patients. Antiviral Therapy 2002; 7:S101. Abstract 122.
21. Quan Y, Gu Z, Li X, Liang C, Parniak MA & Wainberg MA. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. Journal of Molecular Biology 1998; 277:237-247.
22. Krebs R, Immendorfer U, Thrall SH, Wohrl BM & Goody RS. Single- step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 1997; 36:10292-10300.
23. Feng JY & Anderson KS. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999; 38:9440-9448.
24. Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH & Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids. Proceedings of the National Academy of Sciences, USA 1999; 96:10027-10032.
25. Quan Y, Gu Z, Li X, Li Z, Morrow CD & Wainberg MA. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. Journal of Virology 1996; 70:5642-5645.
26. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR & Wainberg MA. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Research 1997; 25:4532-4536.
27. Oude Essink BB, Back NKT & Berkhout B. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Research 1997; 25:3212-3217.
28. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G & Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
29. Boyer PL & Huges SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 1995; 39:1624-1628.
30. Back NK & Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 1997; 41:2484-2491.
31. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP & Wainberg MA. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. Journal of Virology 2002; 76:1753-1761.
32. Götte M, Arion D, Parniak MA & Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. Journal of Virology 2000; 74:3579-3585.
33. Boyer PL, Sarafianos SG, Arnold E & Hughes SH. The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. Journal of Virology 2002; 76:3248-3256.
34. Naeger LK, Margot NA & Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Therapy 2001; 6:115-126.
35. Melby T, Tortell S, Thorborn D, Pearce G, Spreen W, Scott J, Madison S, Lafon S & Lanier ER. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Presented at: 8th Conference on Retroviruses & Opportunistic Infections; February 4-8 2001; Chicago, Ill., USA. Abstract 448.
36. Larder BA, Kemp SD & Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
37. Masquelier B, Descamps D, Carriere I, Ferchal F, Collin G, Denayrolles M, Ruffault A, Chanzy B, Izopet J, Buffet-Janvresse C, Schmitt MP, Race E, Fleury HJ, Aboulker JP, Yeni P & Brun-Vezinet F. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study. Antiviral Therapy 1999; 4:69-77.
38. Tian H, Whitcomb JM, Limoli K et al. Zidovudine/lamivudine co-resistance is preceded by a transient period of zidovudine hypersensitivity. Antiviral Therapy 1998; 3(Suppl. 1):22. Abstract 30.
39. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
40. Margot NA, Johnson A, Coakley DF, Cheng AK & Miller MD. Final 48-week genotypic and phenotypic analyses of study 907: tenofovir DF added to stable background regimens. Presented at: 9th Conference on Retroviruses & Opportunistic Infections; February 24-28 2002; Seattle, Wash., USA. Poster 414-W.
41. Miller MD, Margot NA, Hertogs K, Larder B & Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples. Presented at: 40th Interscience Conference on Antimicrobial Agents & Chemotherapy; September 17-20, 2000; Toronto, ON, Canada. Abstract 2115.
42. Eron JJ, McClernon D, Pierce A, Sawyerr G, Gao H, St Clair M, Tolson J, Capuano G, Hernandez J & Snidow J. M184V selection in suppressed subjects at week 24 may not be associated with treatment outcome (NZTA4002). Presented at: 9th Conference on Retroviruses & Opportunistic Infections; February 24-28, 2002; Seattle, Wash., USA. Abstract 570-T.
43. Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O & Gertoft J. Genotypic and phenotypic changes in antiretroviral-naive patients experiencing failure on randomised treatment with abacavir, didanosine and stavudine. Antiviral Therapy 2002; 7:S125. Abstract 153.
44. Stone C, Ait-Khaled M, Craig C & Tisdale M. HIV-1 reverse transcriptase mutations identified by in vitro selection with tenofovir (TDF) ± abacavir and tenofovir ± lamivudine. Antiviral Therapy 2002; 7:S37. Abstract 44.
45. Bazmi HZ, Hammond JL, Cavalcanti SCH, Chu CK, Schinazi RF & Mellors JW. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β -D-dioxolane-guanosine and suppress resistance to 3′-azido-3′ -deoxythymidine. Antimicrobial Agents & Chemotherapy 2000; 44:1783-1788.
46. White KL, Margot NA, Petropoulos CJ, Wrin T, Naeger LK & Miller MD. Enzymatic analyses and replication capacity of HIV-1 reverse transcriptase mutants K65R and K65R+M184V. Presented at: XIV International AIDS Conference; July 7-12 2002; Barcelona Spain. Abstract MoPe3033.
47. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT & Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.
48. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14:163-171.
49. Selmi B, Boretto J, Sarfati SR, Guerreiro C & Canard B. Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. Journal of Biological Chemistry 2001; 276:48466-48472.
50. Shah FS, Curr KA, Hamburgh ME, Parniak M, Mitsuya H, Arnez JG & Prasad VR. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry 2000; 275:27037-27044.
51. Miller M, Margot N, McColl D, Wrin T, Coakley D & Cheng A. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). Antiviral Therapy 2003; 8:S151. Abstract 135.
52. Ait-Khaled M, Lanier R, Richards N, Stone C, Griffin P, Gibb DM & Walker AS on behalf of PENTA 5 study team, Craig C, Loeloger AE & Tisdale M. Zidovudine appears to prevent selection of K65R and L74V mutations normally selected by abacavir mono- or combination therapies not containing zidovudine. Antiviral Therapy 2002; 7:S107. Abstract 129.
53. Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B & Borroto-Esoda K. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. Journal of Acquired Immune Deficiency Syndromes 2002; 29:11-20.
54. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
55. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA & Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine 1994; 121:263-268.
56. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA 1995; 92:2398-2402.
57. Kavlick MF, Wyvill K, Yarchoan R & Mitsuya H. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. Journal of Infectious Diseases 1998; 177:1506-1513.
58. Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA & Merigan TC. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. Journal of Infectious Diseases 1995; 172:70-78.
59. Ross L, Liao Q, Henry K, Cohen C, Hirani A, Fisher R, St Clair M & Hernandez J. Choice of co-nucleoside analog in d4T-treated subjects may influence the pattern of thymidine analog mutations (TAMs) and multi-nucleoside resistance mutations (MNRs). Presented at: 9th Conference on Retroviruses & Opportunistic Infections; February 24-28 2002; Seattle, Wash., USA. Poster 568-T.
60. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, Ferchal F & Molina JM. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. Journal of Infectious Diseases 2001; 184:781-784.
61. Palmer S, Shafer RW & Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999; 13:661-667.
62. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, Sturmer M, Staszewski S, Ren J, Stammers DK, Stuart DI & Pauwels R. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrobial Agents & Chemotherapy 1999; 43:1961-1967.
63. Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C, Ruffault A, Mohammed AS, Cottalorda J, Schmuck A, Calvez V, Dam E, Fleury H & Brun-Vezinet F; ANRS AC11 Resistance study group. French Agence Nationale de Recherches sur le SIDA. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrobial Agents & Chemotherapy 2001; 45:1836-1842.
64. Lennerstrand J, Stammers DK & Larder BA. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrobial Agents & Chemotherapy 2001; 45:2144-2146.
65. Lennerstrand J, Hertogs K, Stammers DK & Larder BA. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. Journal of Virology 2001; 75:7202-7205.
66. Meyer PR, Lennerstrand J, Matsuura SE, Larder BA & Scott WA. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. Journal of Virology 2003; 77:3871-3877.
67. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
68. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93.
69. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: reanalysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
70. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly & Clotet B; Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
71. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR & Graham NM; VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-588.
72. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: US Dept of Health and Human Services; 2001. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_111003.pdf. Accessed November 10, 2003.
73. The EuroGuidelines Group for HIV. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15:309-320.
74. Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cecile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C & Brun-Vezinet F. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antiviral Therapy 2002; 7:211-218.
75. Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM & Katzenstein DA. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. Journal of Acquired Immune Deficiency Syndromes 2002; 31:121-127.
76. Parkin NT, Chappey C & Petropoulos CJ. Mutations in HIV-1 protease associated with resistance to amprenavir contribute towards phenotypic resistance to lopinavir. Antiviral Therapy 2002; 7:S23. Abstract 24.
77. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS & Petropoulos CJ. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. Journal of Acquired Immune Deficiency Syndromes 2002; 31:128-136.
78. Haubrich RH, Kemper CA, Hellmann NS & the CCTG Study Team. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-F40.
79. Haubrich R, Keiser P, Kemper C et al. & the CCTG Study Team. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antiviral Therapy 2001; 6(Suppl. 1):63. Abstract 80.
80. Wegner S, Wallace M, Tasker S, Aronson N, Blazes D, Tamminga C, Fraser S, Stephen K, Jagodzinski L, Vahey M, Tracy L, Rinehart A, Graham N, Hertogs K & Birx D. Long-term clinical efficacy of resistance testing: results of the CERT trial. Antiviral Therapy 2002; 7:S129. Abstract 158.
81. Kellam P, Boucher CAB & Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proceedings of the National Academy of Sciences, USA 1992; 89:1934-1938.
82. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A & Larder BA. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. Journal of Virology 1996; 70:5930-5934.
83. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J & Larder BA. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 1992; 165:105-110.
84. Cho YK, Sung H, Ahn SH, Bae IG, Woo JH, Won YH, Kim DG & Kang MW. Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea. Journal of Clinical Microbiology 2002; 40:1319-1325.
85. Marcelin AG, Wirden M, Delaugerre C, Viegas P, Simon A, Katlama C & Calvez V. Selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors occurs step by step and through two different pathways. Antiviral Therapy 2002; 7:S34. Abstract 40.
86. Ross LL, Johnson M, Hernandez J et al. d4T-based combination therapy selects for 'ZDV like' HIV-1 resistance mutations in ZDV-naive adult patients. Presented at: 39th International Conference on Antimicrobial Agents & Chemotherapy; September 26-29 1999; San Francisco, Calif., USA. Abstract 429.
87. Maxeiner HG, Keulen W, Schuurman R, Bijen M, de Graaf L, van Wijk A, Back N, Kline MW, Boucher CA & Nijhuis M. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. Journal of Infectious Diseases 2002; 185:1070-1076.
88. Lacey SF & Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrobial Agents & Chemotherapy 1994; 38:1428-1432.
89. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 1994; 170:1157-1164.
90. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA & Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. New England Journal of Medicine 1995; 333:1662-1669.
91. Miller MD, Zhong L, Chen S, Margot NA & Wulfsohn M. Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviral-experienced patients. Antiviral Therapy 2002; 7:S12. Abstract 14.
92. Viread [package insert]. Foster City, Calif., USA: Gilead; 2002.
93. Kuritzkes DR, Bassett RL, Young RK et al., for the ACTG 306 and 370 Protocol Teams. Rate of emergence of thymidine analogue resistance mutations in HIV-1 reverse transcriptase selected by stavudine or zidovudine-based regimens in treatment-naive patients. Antiviral Therapy 2002; 7:S31. Abstract 36.
94. Sarmati L, Nicastri E, Parisi SG, D'Ettorre G, Narciso P, Mancino G, Gallo I, Abbadessa V, Dalle NE, Traina C, Vullo V & Andreoni M. Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations. Journal of Medical Virology 2001; 65:631-636.
95. Hertogs K, Bloor S, De Vroey V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, van Houtte M, Miller V & Larder BA. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrobial Agents & Chemotherapy 2000; 44:568-573.
96. Gallego O, Briones C, Corral A & Soriano V. Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pretreated HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes 2000; 25:95-96.
97. Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC & Zazzi M. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. Journal of Infectious Diseases 2002; 185:898-904.
98. Walter H, Schmidt B, Werwein M, Schwingel E & Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrobial Agents & Chemotherapy 2002; 46:89-94.
99. Richman DD, Meng TC, Spector SA, Fischl MA, Resnick L & Lai S. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 1994; 7:135-138.
100. Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M & Babiker A. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. Journal of Infectious Diseases 2002; 186:617-625.
101. Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Munoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT & Babiker AG. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1 infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (The PENTA 5 Trial). Antiviral Therapy 2002; 7:293-303.
102. Murphy R, Santana J, Squires K, Yangco B, Peterson D, Adams J, Mauney J, Perry M, Grosso R, Tudor J, Stevens M & the Start Observation Team. START observational study: longitudinal follow-up of virologic and immunologic responses in START I and START II patients. Presented at: 8th Conference on Retroviruses & Opportunistic Infections; February 4-8 2001; Chicago, Ill., USA. Abstract 314.
103. Havlir D, Hellman N, Petropoulos C et al. Viral rebound in the presence of indinavir without protease inhibitor resistance. Presented at: 6th Conference on Retroviruses & Opportunistic Infections; January 31-February 4 1999; Chicago, Ill., USA. Abstract LB12.
104. Eron J, Arduino R, Junod P et al. Genotypic patterns in virologic failures on lamivudine/zidovudine-based triple and quadruple therapy (NZTA4002). Presented at: 40th Interscience Conference on Antimicrobial Agents & Chemotherapy; September 17-20 2000; Toronto, ON, Canada. Abstract 1274.
105. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R & Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. Journal of Infectious Diseases 1999; 179:808-816.
106. Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R & Kleim JP. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14:1195-1201.
107. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV & Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. Journal of Virology 1998; 72:2422-2428.
108. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S & Sun E; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 2002; 346:2039-2046.
109. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Meyer WA, Klingman K, Squires KE, Snyder S & Kuritzkes DR. ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. Antiviral Therapy 2003; 8(Suppl. 1):S194. Abstract 41.
110. Winston A, Mandalia S, Pillay D, Gazzard B & Pozniak A. The prevalence and determinants of the K65R mutation in HIV reverse transcriptase in tenofovir naive patients. Presented at: XIV International AIDS Conference; July 7-12 2002; Barcelona, Spain. Abstract TuPeB4600.
111. Farthing C, Khanlou H & Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in treatment naive HIV-infected patients. Antiviral Therapy 2003; 8(Suppl. 1):S195. Abstract 43.
112. Gallant JE, Rodriguez AE, Weinberg W et al. for the ESS30009 Study Team. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. Presented at: 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. September 14-17 2003; Chicago, Ill., USA. Abstract LB-1722A.
113. Sharma PL & Crumpacker CS. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. Journal of Virology 1997; 71:8846-8851.
114. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK & Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine 2001; 344:472-480.
115. Deeks SG, Sinclair E, Harris JM et al. HIV-specific cellular immunity and partial control of drug-resistant vs wild-type viremia. Presented at: 9th Conference on Retroviruses & Opportunistic Infections; February 24-28 2002; Seattle, Wash., USA. Abstract 108.
116. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD & D'Aquila RT. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. Journal of Infectious Diseases 2000; 181:904-911.
117. Miller MD, Margot NA & Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: integrated analyses of studies 902 and 907. Presented at: 9th Conference on Retroviruses & Opportunistic Infections; February 24-28 2002; Seattle, Wash., USA. Abstract 43.
118. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, Gastaut JA, Gallais H, Moreau J & Fantini J. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. Journal of Clinical Microbiology 1999; 37:4099-4106.
119. Lanier ER, Irlbeck D, Ross L, Gerondelis P, Underwood M, Parkin N, Chappey C & St Clair M. Prediction of NRTI Options by Linking Reverse Transcriptase Genotype to Phenotypic Breakpoints. Presented at: 10th Conference on Retroviruses & Opportunistic Infections; February 10-14 2003; Boston, Mass., USA. Abstract 586.
120. Keiser P. Role of sequencing in therapy selection. Journal of Acquired Immune Deficiency Syndromes 2002; 29(Suppl. 1):S19-S27.
121. Gallant J. Strategies for long-term success in the treatment of HIV infection. Journal of the American Medical Association 2000; 283:1329-1334.